Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating Expenses:    
Research and development $ 99,899 $ 472,862
Research and development - related parties 267,053 30,605
General and administrative 2,542,231 995,328
General and administrative - related parties 39,120 68,067
Total Operating Expenses 2,948,303 1,566,862
Loss From Operations (2,948,303) (1,566,862)
Other (Expense) Income:    
Gain on settlement of payables and accrued expenses 723,764
Other income - related parties 240,000
Interest expense (112,933) (152,916)
Interest expense - related parties (13,949) (19,848)
Loss on extinguishment of convertible notes payable, net (9,737) (886,736)
Change in fair value of derivative liabilities (13,229,308)
Offering costs allocated to warrant liabilities (604,118)  
Change in fair value of accrued issuable equity (9,405)
Total Other Expense, Net (13,255,686) (819,500)
Loss Before Income Taxes (16,203,989) (2,386,362)
Income tax benefit 5,404 5,102
Net Loss (16,198,585) (2,381,260)
Other Comprehensive Income:    
Foreign currency translation adjustments 189,348 (1,844,205)
Total Comprehensive Loss $ (16,009,237) $ (4,225,465)
Basic and Diluted Net Loss per Common Share (in Dollars per share) $ (0.58) $ (0.14)
Weighted Average Number of Common Shares Outstanding: (in Shares) 27,953,302 16,840,668